Tom completed his PhD in Professor Zilbauer’s lab in 2022, where he used patient-derived organoids to study the functional role of IBD-associated DNA methylation changes in the human intestinal epithelium. He now works between the Zilbauer lab and the Milner Therapeutics Institute, where he aims to develop the organoid model as a tool for drug discovery and development, including through their application to drug and gene perturbation screening.
Immunofluorescence images of intestinal organoids
Key publications
Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease. Dennison TW, Edgar RD, Payne F, Nayak KM, Ross ADB, Cenier A, Glemas C, Giachero F, Foster AR, Harris R, Kraiczy J, Salvestrini C, Stavrou G, Torrente F, Brook K, Trayers C, Elmentaite R, Youssef G, Tél B, Winton DJ, Skoufou-Papoutsaki N, Adler S, Bufler P, Azabdaftari A, Jenke A, G N, Thomas N, Miele E, Al-Mohammad A, Guarda G, Kugathasan S, Venkateswaran S, Clatworthy MR, Castro-Dopico T, Suchanek O, Strisciuglio C, Gasparetto M, Lee S, Xu X, Bello E, Han N, Zerbino DR, Teichmann SA, Nys J, Heuschkel R, Perrone F, Zilbauer M.
Gut. 2024 Aug 8;73(9):1464-1477. doi: 10.1136/gutjnl-2024-332043. PMID: 38857990; PMCID: PMC11347221.